Treats Duchenne muscular dystrophy (DMD). Sold as Duvyzat. Every FDA application for this active ingredient. Orphan exclusivity to Mar 21, 2031
As of Nov 22, 2026, FDA lists 1 application for Givinostat hydrochloride (sold as Duvyzat), first approved Mar 21, 2024, with 0 new uses approved and 0 published complete response letters.
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Mar 21, 2024 | DuvyzatNDA 217865 · New molecular entity | Italfarmaco | 0 | Marketed |
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Duvyzat | Part D | $9.7M | +397% | 31 |
| Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years OldDuchenne Muscular Dystrophy · Italfarmaco | Phase 2 | Recruiting | Jan 10, 2025 |
| Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia VeraPolycythemia Vera · Italfarmaco | Phase 3 | Recruiting | Oct 23, 2023 |
| Efficacy, Safety and Tolerability of Givinostat in Non-ambulant Patients With Duchenne Muscular DystrophyDuchenne Muscular Dystrophy · Italfarmaco | Phase 3 | Recruiting | Jul 6, 2023 |
| Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative NeoplasmsChronic Myeloproliferative Neoplasms · Italfarmaco | Phase 2 | Active, not recruiting | Jan 7, 2013 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Mechanisms, targets, withdrawals and boxed warnings are from ChEMBL (EMBL-EBI, CC BY-SA 3.0), matched by ingredient name. How trials ended is TrialPanorama's classification of ClinicalTrials.gov records (Wang et al. 2025, Apache-2.0), matched by the intervention name each trial registered. Drugs@FDA